The immune system produces a diverse array of antibodies by a series of DNA transactions that require programmed DNA damage. Ig transcription units are assembled by random joining of variable (V), diversity (D), and joining (J) gene segments by a site-specifi c recombination reaction mediated by RAG1 and RAG2 proteins in developing B cells ( 1, 2 ) . Later, during immune responses, antigen-specifi c clones of B cells are selectively expanded in structures called germinal centers (GCs), where they undergo Ig somatic mutation and class switch recombination (CSR) ( 3, 4 ) . Somatic hypermutation (SHM) introduces nontemplate nucleotide substitutions into the Ig variable gene ( 5 ) , which can alter the binding affi nity of the antibody molecule. If the affi nity is enhanced, the resulting B cell clone is selectively expanded, ultimately resulting in affi nity maturation of the antibody response ( 3, 4 ) . CSR is a region-specifi c deletional recombination reaction that replaces one antibodyconstant region for another, thereby altering antibody eff ector function ( 6 -11 ) . Class switching does not involve the variable regions, and therefore switched antibodies retain their antigenic specifi city. Although somatic mutation and class switching are fundamentally diff erent DNA transactions, they are initiated in the nucleus by the same enzyme, activation-induced cytidine deaminase (AID) ( 12 -14 ) , which introduces uracil:guanine mismatches in transcribed single-stranded (ss) Ig DNA ( 15 -19 ) .
In addition to its eff ects on Igs , AID produces off -target DNA damage, including point mutations in oncogenes such as bcl6 or c-myc ( 20 -23 ) , and it also induces double-stranded DNA breaks in Igs that serve as substrates for chromosome translocations ( 24 -26 ) . DNA damage by AID is minimized in part because AID Activation-induced cytidine deaminase (AID) is a mutator enzyme that initiates somatic mutation and class switch recombination in B lymphocytes by introducing uracil:guanine mismatches into DNA. Repair pathways process these mismatches to produce point mutations in the Ig variable region or double-stranded DNA breaks in the switch region DNA. However, AID can also produce off-target DNA damage, including mutations in oncogenes. Therefore, stringent regulation of AID is required for maintaining genomic stability during maturation of the antibody response. It has been proposed that AID phosphorylation at serine 38 (S38) regulates its activity, but this has not been tested in vivo. Using a combination of mass spectrometry and immunochemical approaches, we found that in addition to S38, AID is also phosphorylated at position threonine 140 (T140). Mutation of either S38 or T140 to alanine does not impact catalytic activity, but interferes with class switching and somatic hypermutation in vivo. This effect is particularly pronounced in haploinsufficient mice where AID levels are limited. Although S38 is equally important for both processes, T140 phosphorylation preferentially affects somatic mutation, suggesting that posttranslational modifi cation might contribute to the choice between hypermutation and class switching.
not PKA ( Fig. 1 E ) . The PKC family is composed of at least 10 serine/threonine kinases, and anti-p140 and -p38 was reactive to varying degrees with recombinant AID after in vitro phosphorylation with the diff erent isoforms ( Fig. 1 F ) . We conclude that AID is phosphorylated at position T140 and that this site of posttranslational modifi cation resembles S38 in that it is not B cell specifi c.
To determine whether T140 is essential for catalytic activity, we compared wild-type and AID-T140A for their ability to revert an inactivating point mutation in a kanamycin resistance encoding plasmid in Escherichia coli ( 19 ) . Reversion of the point mutation (CCA P94 to CTA L94 ) by cytidine deamination confers kanamycin resistance, which is assayed by colony formation ( 19 ) . AID-T140A, AID-S38A, and the double mutant (AID-ST/AA) were indistinguishable from expression is restricted to activated B cells within GCs ( 13 ) by a requirement for PAX5 and E47 transcription factors ( 27, 28 ) .
AID levels are limiting for CSR and hypermutation ( 29 -31 ) , and they are known to be regulated by microRNA-155, which controls the half-life of AID mRNA ( 30, 32 ) . In addition, the concentration of AID in the nucleus is limited by a combination of active export and selective nuclear degradation ( 33 -36 ) . Finally, biochemical and tissue culture experiments indicate that a fraction of AID is posttranslationally modifi ed by phosphorylation of serine 38 (S38) and that this modifi cation may also regulate AID activity ( 29, 37, 38 ) .
S38 is thought to be a target of c-AMP -dependent protein kinase A (PKA) because S38 is part of a PKA consensus site and can be phosphorylated in vitro by PKA ( 37 ) . Furthermore, coimmunoprecipitation experiments showed that AID is physically associated with PKA ( 37, 38 ) . In biochemical assays phosphorylation at S38 is essential for AID to associate with replication protein A (RPA), a single stranded DNA binding protein, and the interaction is required for AID to access actively transcribed DNA ( 37 ) . Consistent with this observation, AID phosphorylated at S38 is enriched in chromatin ( 29 ) .
Although the role of S38 phosphorylation has not been tested in vivo, mutating S38 to alanine (AID S38A ) results in catalytically intact AID, which may have an altered substrate preference in biochemical assays in vitro ( 29, 37, 39 ) . Expression of AID S38A has also been reported to variably decrease CSR assayed in AID-defi cient B cells in vitro (10 -80% of wild type) ( 29, 37, 38, 40 ) and SHM and gene conversion in chicken DT40 B cells (15% of wild type) ( 41 ) . Further confounding the question of the function of S38 phosphorylation is the fact that zebrafi sh AID lacks a serine at this position, yet retains activity in CSR and gene conversion ( 41 -43 ) .
In this study, we report on a novel site of AID phosphorylation at threonine 140 (T140) and examine the impact of S38 and T140 phosphorylation on CSR and SHM in vivo.
RESULTS
To examine posttranslational modifi cation of AID, we purifi ed the protein from B cells cultured with LPS and IL-4 and subjected the material to mass spectrometry. Analysis of purifi ed AID confi rmed phosphorylation at peptides containing S38 (p38), and tyrosine 184 (p184) ( 29, 37 ) and revealed additional phosphorylation at T140 (p140; Fig. 1 A ) .
To confi rm that AID is phosphorylated at T140 in vivo, we produced AID-p140 phosphospecifi c antibodies (antip140). Anti-p140 was reactive with AID purifi ed from B cells stimulated with LPS and IL-4, but was not reactive with AID-T140A ( Fig. 1 B ) . The level of anti-p140 reactivity in cultured B cells diff ered depending on the stimulus with the highest levels found with CpG ( Fig. 1 C ) . However, phosphorylation at AID-T140 was not B cell specifi c and could also be detected in NIH-3T3 NTZ cells expressing AID ( Fig. 1 D ) . Finally, anti-p140 did not react with recombinant AID produced in bacteria, but was reactive with AID phosphorylated in vitro with protein kinase C (PKC) catalytic subunit and displayed a > 40% increase in isotype switching ( Fig. 2 J ) . We conclude that AID levels are rate limiting and that superphysiological levels can drive higher rates of isotype switching.
To examine the physiological function of AID phosphorylation at positions S38 and T140, we produced mice that carry S38A or T140A mutations in AID , AID S38A , and AID T140A , respectively (Fig. S1 , available at http://www.jem.org/cgi/ content/full/jem.20081319/DC1). AID S38A and AID T140A mutant B cells developed normally (not depicted) and were assayed for CSR to IgG1 after stimulation with LPS and IL-4 in culture. Cell division was monitored by labeling cells with CFSE and tracking dye dilution by fl ow cytometry. AID protein levels expressed by wild-type, AID S38A , and AID T140A B cells were indistinguishable when measured by Western blotting ( Fig. 3 A ) , and heterozygous AID +/ Ϫ , AID S38A/ Ϫ , and AID T140A/ Ϫ expressed half as much AID as their homozygous counterparts ( Fig. 3 A ) . AID S38A and AID T140A B cells divided normally in response to LPS and IL-4, but were impaired in switch recombination to IgG1 ( Fig. 3 , B and C ). AID S38A mutant B cells showed 32% the level of CSR to IgG1 of wild-type controls, whereas AID T140 produced a milder defect resulting in 87% of wild-type CSR ( Fig. 3 , B and C ). In both cases, the defect was exacerbated in haploinsuffi cient mice. Although AID +/ Ϫ B cells displayed IgG1 switching, 80% of wild-type B cells, AID S38A/ Ϫ , and AID T140A/ Ϫ showed 4 and 45% the level of wild-type B cells, respectively ( Fig. 3 , B and C ). This relative decrease was consistent within each experiment, despite overall switching rates varying from experiment to experiment ( Fig. 3 , B and C ). We also measured mutation within the region 5 Ј of the S switch repeats. Similar to CSR, AID S38A and AID T140A had mutation rates of 25 and 85%, respectively, compared with WT ( Fig. 3 D ) . Because diff erent stimulation conditions may result in diff erential levels of AID phosphorylation ( Fig. 1 C ) , we measured isotype switching to IgG3. After stimulation with LPS or LPS and anti-dextran in culture, AID S38A B cells showed 19 or 16% the level of CSR to IgG3 of wildtype controls, whereas AID T140A produced a milder defect resulting in 71 or 52% wild-type CSR ( Fig. 3 , E and F ). We conclude that both AID-S38 and -T140 phosphorylation are required for physiological levels of CSR, but neither is essential for this reaction.
To examine the role of AID phosphorylation in SHM, we cloned and sequenced the DNA region downstream of IgJ H 4 from purifi ed lymph node GC B cells ( 46 ) . The eff ect of AID S38A on somatic mutation was similar to CSR, resulting in 30% of wild-type activity ( Fig. 4 A ) . In contrast, AID T140A had more profound eff ects on somatic mutation than CSR, resulting in 45% of wild-type activity, which was not signifi cantly diff erent from AID S38A ( Fig. 4 A ) . Similar results were obtained from Peyer ' s patch B cells, where mutation rates for AID S38A and AID T140A were 20 and 40% of controls, respectively ( Fig. 4 B ) . Haploinsuffi ciency by itself resulted in a mild decrease in hypermutation with 70% hypermutation activity in AID +/ Ϫ versus wild type ( Fig. 4 A ) . Haploinsuffi ciency magnifi ed the defect in hypermutation of AID S38A/ Ϫ and AID T140A/ Ϫ , with neither statistically rising above the background levels of mutation wild type in this assay ( Fig. 2 A ) ( 29 ) . Thus, these mutations do not alter AID catalytic activity as assayed in E. coli .
To determine whether there is interdependence between S38 and T140 phosphorylation, we expressed AID, AID-S38A, or AID-T140A in stimulated AID Ϫ / Ϫ B cells and performed Western blotting experiments with anti-p140 andp38 antibodies. We found that AID-S38A was normally phosphorylated at position T140 and, conversely, that AID-T140A was normally phosphorylated at S38. We conclude that the two sites of phosphorylation are not interdependent ( Fig. 2 B ) .
AID is phosphorylated in 3T3 fi broblasts ( Fig. 1 D ) and mutates indicator substrates when it is expressed in these cells. Mutator activity can be measured by reversion of a green fl uorescent protein indicator containing a premature stop codon (NIH-3T3 NTZ cells [ 44 ] ). When assayed by FACS or sequencing, AID-S38A and -T140A showed < 15 and < 50% of wild-type levels, respectively ( Fig. 2 , C and D ) ( 29 ) . We conclude that T140 is required for normal levels of mutation in NIH-3T3 NTZ cells in vitro.
AID can be assayed for its ability to induce CSR in B cells in vitro by retroviral complementation of AID-defi cient B cells stimulated with LPS and IL-4 ( 45 ). Because AID expression levels may impact on the results of the assay, we used two retroviral vectors that directed diff erent levels of AID expression ( Fig. 2 E ) . B cell retroviral infection with PMX-AID ( 25 ) or MK-AID, which contains a mutant Kozak sequence, results in AID levels that are 10-or 2.5-fold higher than physiological levels, respectively ( Fig. 2 E ) . Consistent with the high levels of AID expression, B cells infected with PMX-AID switched to IgG1 at higher effi ciency than cells infected with MK-AID ( Fig. 2, F and H ) . AID mutants showed varying degrees of activity in this assay ( Fig. 2, F and H ) . High levels of AID-T140A expression reconstituted nearly 95% of control levels of class switching ( Fig. 2, F and G ) . In contrast, lower levels of AID-T140A expression resulted in 50% of control levels of switching ( Fig. 2, H and I ). As previously reported, AID-S38A mutants varied in activity depending on expression levels ranging from nearly undetectable to 60% of control levels ( Fig. 2, G and I ) ( 29, 37, 38, 40 ) . High-level expression of the double mutant, AID-ST/AA, resulted in a modest drop in class switching compared with AID-S38A, 35 versus 55% of control levels of switching, respectively, which is consistent with an additive eff ect of the two mutations ( Fig. 2 , F and G ). We conclude that phosphorylation of S38 and T140 are important for class switching in LPS-and IL-4 -stimulated B cells. Furthermore, higher levels of AID expression drive higher levels of switching to IgG1 and diminish the requirement for S38 or T140 phosphorylation. Therefore, the precise contribution of these posttranslational modifi cations to AID function is diffi cult to evaluate in this assay.
To determine if AID protein levels are a rate-limiting factor in CSR, we augmented AID levels in wild-type LPS-and IL-4 -stimulated B cells with retrovirally expressed AID and measured isotype switching to IgG1. Compared with wild type alone or wild type transduced with empty PMX retrovirus, cells supplemented with AID from the PMX-AID retrovirus S38A is active at between 20 and 35% of wild-type levels in hypermutation and CSR in vivo. One way to reconcile these results would be to posit that association between AID and RPA is only required for a subset of AID substrates that do not stabilize ss regions spontaneously. For example, ssDNA in switch regions is stabilized spontaneously by R-loops, but this does not occur in Ig variable region DNA. This model might predict that the S38A mutation would preferentially interfere with Ig variable region hypermutation ( 49, 50 ) . However, the AID S38A mutation aff ects switching and mutation equally; therefore, the mechanism by which S38 phosphorylation alters AID function is likely to be independent of whether the ssDNA substrate is created by R-loops. An alternative nonexclusive explanation for our results is that S38 phosphorylation enhances AID activity by facilitating its interaction with chromatin ( 29 ) .
Biochemical studies with AID purifi ed from insect cells assayed on artifi cial substrates showed that S38A mutation does not alter overall AID activity, but shifts target preference in a way that might result in specifi c loss of activity on hotspots found in the Ig switch region ( 39 ) . This in vitro bias is not consistent with our mutation data in transfected fi broblasts or GC B cells because we fi nd lower levels of SHM in all cases and the selective hotspot bias found in the in vitro transcription systems would not aff ect the rate of SHM ( 29 ) .
Previous coimmunoprecipitation and in vitro kinase experiments suggest that PKA phosphorylates AID at S38; the importance of this kinase in regulating AID is supported by the fi nding that inhibition of its activity in B cells inhibits class switching ( 37, 38 ) . Our experiments indicate that T140 is not a PKA target site, and that S38 can be phosphorylated by either PKA or PKC in vitro ( Fig. 1 E ) . In addition, PKC family members overlap in their preference to phosphorylate T140 or S38 in vitro ( Fig. 1 F ) and S38 or T140 phosphorylation is nonexclusive ( Fig. 2 B ) . Thus, AID activity may be modulated by phosphorylation on one or both sites, depending on which kinase is activated. The PKC family is composed of at least 10 serine/threonine kinases, many of which are expressed in activated B cells ( 51, 52 ) . They have been implicated in a wide variety of cellular processes, including growth, diff erentiation, tolerance, immunity, and tumor development ( 51 ) . Which family members phosphorylate AID and the precise pathways that regulate phosphorylation in vivo remains to be determined.
How T140 phosphorylation modulates AID activity is not known, but this modifi cation diff ers from S38 in that it preferentially aff ects somatic mutation. Diff erential regulation found in AID Ϫ / Ϫ lymph node GC B cells ( Fig. 4 A ) . Similar, but slightly less pronounced, eff ects were found in chronically stimulated Peyer ' s patch GC B cells ( Fig. 4 B ) . We conclude that both AID-S38 and -T140 phosphorylation are required for optimal somatic mutation and that the T140 has a more profound eff ect on this reaction than on CSR ( Fig. 4 C ) .
AID-defi cient mice and humans have large GCs compared with controls ( 12, 14 ) . To determine whether this eff ect is caused by loss of AID protein or its activity, we measured the number of GC B cells in AID Ϫ / Ϫ , AID +/ Ϫ , AID T140A/-, AID S38A/ Ϫ , and wild-type mice ( Fig. 5, A and B ) . We found that the amount of AID activity was inversely proportional to the size of the GC response. AID Ϫ / Ϫ mice showed the highest number of GC B cells, wild-type mice the fewest, and AID +/ Ϫ haploinsuffi cient mice were intermediate between the two ( Fig. 5, A and B ) . Decreasing AID activity, but not protein, in AID S38A/ Ϫ mice resulted in an increase in the number of GC B cells proportional with the relative decrease in activity when compared with AID +/ Ϫ controls ( Fig.  5, A and B ) . We conclude that the number of GC B cells in immunized mice is inversely proportional to the amount of AID activity.
DISCUSSION
Mice and humans defi cient in AID have larger GCs than controls ( 12, 14 ) . In this study, we observe larger GCs in AID-haploinsuffi cient mice together with further enlargement in AID S38A/ Ϫ mice, indicating that the GC phenotype is directly related to the level of AID activity. AID activity might impact GC size by a variety of mechanisms, including antibody gene or generalized genomic damage. For example, increased AID activity could result in higher rates of detrimental antibody gene mutation, leading to loss of affi nity, loss of expression, or development of self-reactive antibodies ( 3, 4 ) . Conversely, higher rates of off -target genomic damage by AID may lead to mutations that result in cell death ( 47 ) . Irrespective of the mechanism, the magnitude of the eff ect of AID levels on GC size emphasizes the importance of AID regulation in vivo.
Phosphorylation of AID at position S38 is believed to facilitate the interaction between AID and RPA, a cofactor that is required for AID to access transcribed DNA in vitro ( 37 ) . RPA binds to ssDNA and it was proposed that RPA might stabilize ssDNA liberated during transcription to serve as a substrate for AID ( 48 ) . Consistent with this idea, AID-S38A is inactive on transcribed dsDNA in the absence of RPA, while retaining catalytic activity on ssDNA ( 37 ) . Nevertheless, AID- This cannot be ascribed to a general absence of the factors that mediate hypermutation because the DNA 3 Ј of the I promoter and the switch regions themselves are mutated by AID in LPS-and IL-4 -stimulated B cells. Indeed, the amount of mutation in switch regions in AID-T140A -expressing B cells is directly proportional to the amount of class switching and diff ers from Ig variable region gene mutation, which is more severely aff ected ( Fig. 4 C ) . One explanation for the disparity between the eff ects of AID-T140A on switching and mutation would be that there are specifi c requirements for AID in the two reactions. This idea is supported by the fi nding that mutations in the amino or carboxyl terminal regions of AID preferentially aff ect somatic mutation or class switching ( 45, 53 ) . Finding that phosphorylation at T140 preferentially aff ects somatic mutation suggests a mechanism by which AID activity on closely related substrates might be diff erentially regulated. Conditions and primers were previously described ( 29 ) . The NTZ-3T3 assay and GFP gene mutational analysis were performed as previously described 11 d after retrovirus infection ( 33, 44 ) . PCR products were cloned into TOPO-TA cloning kit (Invitrogen) and sequenced with T7 primer. E. coli assays were performed exactly as previously described ( 19 ) .
Protein analysis. Anti-AID and -p38 antibodies were previously described ( 29 ) . To produce anti-p140 antibodies, rabbits were immunized with phosphopeptide GVQIGIM(pT)FKDYFYC (AID 133 -148) coupled to keyhole limpet hemocyanin. Phosphospecifi c antibodies were purifi ed by negative selection on unphosphorylated peptide AID 133 -148 coupled to Sulfolink gel (Thermo Fisher Scientifi c), followed by positive selection on the phosphopeptide. Cells were extracted in lysis buff er (20 mM Tris, pH 8.0, 400 mM NaCl, 1% Nonidet P-40, 0.5 mM EDTA, 25 mM NaF, and 1 mM DTT). For immunoprecipitation, 2 mg of extracts were incubated with anti-AID antibody and protein A -Sepharose (GE Healthcare) for 2 h. For FLAG immunoprecipitation, anti-FLAG agarose beads (Sigma-Aldrich) were incubated with extracts for 2 h and AID was eluted with 0.5 μ g/ml of FLAG peptide (Sigma-Aldrich) in lysis buff er. Western blots were performed on immunoprecipitated protein or on 50 μ g of total cell extracts with the indicated anti-AID antibody; anti-tubulin (Abcam) was used as a loading control. To compare AID levels from retroviral-infected B cells, Western blots were performed on cells sorted for GFP expression. AID purifi cation and mass spectrometry analysis of phosphorylation was performed as previously described on extracts from 10 9 wild-type B cells purifi ed from mouse spleens by depletion with anti-CD43 beads (Miltenyi Biotec) and cultured in RPMI medium, 10% FBS, 5 ng/ml IL-4 (Sigma-Aldrich), and 25 μ g/ml LPS (Sigma-Aldrich) for 72 h ( 29 ).
In vitro phosphorylation. 100 ng of purifi ed recombinant AID protein was incubated with PKA as previously described ( 29 ) or 0.1 U of PKC catalytic subunit or isoforms (Calbiochem) for 30 min at 30 ° C in a buff er containing 40 mM MES, pH 6.0, 1 mM EGTA, 10 mM MgCl 2 , 1 mM DTT, and 0.1 mM ATP.
Online supplemental material. Fig. S1 shows gene-targeting strategy to produce AID S38A and AID T140A mice. The online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20081319/DC1. AID activity is regulated by several mechanisms, including restricted expression, mRNA stability, nuclear degradation, nuclear export, and multiple phosphorylation sites. Although each of these alone appears to have a small eff ect on CSR and SHM, the combined eff ects are dramatic. For example AID haploinsuffi ciency supports rates of 80 and 70% of wild type in CSR and lymph node SHM, respectively ( Fig. 4 C ) . However, CSR is decreased to 5% of AID +/ Ϫ controls, and lymph node SHM was at background levels in AID S38A/ Ϫ mice ( Fig.  4 C ) . Similarly, AID T140A/ Ϫ B cells were severely, but selectively, impaired in lymph node SHM (10% of AID +/ Ϫ vs. 57% for CSR to IgG1; Fig. 4 C ) . Peyer ' s patch B cells supported SHM levels nearly three times higher then lymph node. In this case, SHM rates in AID +/ Ϫ and AID T140A/ Ϫ resemble those of AID and AID T140A in the lymph node ( Fig. 4, A and B ) . Thus, AID appears to be controlled by multiple potentially overlapping mechanisms. We speculate that this type of combinatorial regulation facilitates fi ne control of AID levels, which is required because small imbalances in its expression can result in catastrophic eff ects on genomic stability ( 25 ) .
MATERIALS AND METHODS

Mice.
To produce AID S38A and AID T140A mice, AID S38 or T140 was mutated to alanine using the same gene-targeting strategy (Fig. S1) . The long arm of the targeting vector was 5 kb long with 3 Ј within the intron between AID exons 2 and 3 (Fig. S1 ). The short arm was a 3.3-kb fragment extending with the 3 Ј into the intron between exons 3 and 4. A LoxP-fl anked neomycin-resistance gene was used for positive selection, and a diphtheria toxin gene was used for negative selection. The targeting construct was linearized and transfected into C57BL/6 embryonic stem cells. The genotype was confi rmed by Southern blot and PCR amplifi cation using a primer outside of the targeting construct, followed by sequencing. Mice were crossed to AID Ϫ / Ϫ C57BL/6 mice ( 12 ) to produce AID +/ Ϫ , AID S38A/ Ϫ , or AID T140A/ Ϫ mice used for analysis. The presence of mutants were confi rmed by RT-PCR and sequencing of AID mRNA. All experiments with mice were done according to protocols approved by the Rockefeller University Institutional Animal Care and Use Committee.
Lymphocyte isolation and culturing and retroviral infection. Lymphocyte isolation, cultures, retrovirus infection, and analysis were previously described ( 29 ) . The PMX-MK-AID was the same as the previously described PMX-AID, except the Kozak CCACCATGG was changed to GGTTTATGG. B cells were purifi ed from mouse spleens by depletion with anti-CD43 beads (Miltenyi Biotec) and cultured in 25 μ g/ml LPS (SigmaAldrich) alone for switching to IgG3 or with 5 ng/ml IL-4 (Sigma-Aldrich) for IgG1or with 2.5 ng/ml anti-␣ -␦ -dextran (Fina BioSolutions) for IgG3. Cells were stained with CSFE and/or with biotinylated anti -mouse IgG1 or IgG3 antibodies and streptavidin APC (BD Biosciences).
PCR and mutation analysis. For SHM analysis, age-matched 8 -16-wkold mice were immunized by footpad injected with 50 μ g of NP-CGG (Biosearch Technologies) precipitated in alum and lymph node, and Peyer ' s patches were dissected 11 d after immunization. GC B cells were stained with APC anti-CD19, FITC anti-GL7, and PE anti-FAS antibodies (BD Biosciences) and purifi ed by cell sorting. In two independent experiments, DNA samples were pooled from 2 or 3 separate mice. To amplify the intronic region 3 Ј of JH4, four separate PCR reactions were performed on each sample with PFU polymerase (Stratagene) on genomic DNA from 5,000 equivalent cells. Amplifi ed products were pooled, cloned, and sequenced. The intron region 3 Ј of JH4 was amplifi ed with a common V H J558 family primer (5 Ј -GGAATTCGCCTGACATCTGAGGACTCTGC-3 Ј ) and (5 Ј -CTGGACTTTCGGTTTGGTG-3 Ј ) for 9 cycles at 94 ° C (30 s), at
